1
|
Capaldi D, Akhtar N, Atherton T, Benstead D, Charaf A, De Vijlder T, Heatherington C, Hoernschemeyer J, Jiang H, Rieder U, Ring F, Peter R, Stolee JA, Wechselberger R. Strategies for Identity Testing of Therapeutic Oligonucleotide Drug Substances and Drug Products. Nucleic Acid Ther 2020; 30:249-264. [PMID: 32857010 DOI: 10.1089/nat.2020.0878] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022] Open
Abstract
A risk-based approach for routine identity testing of therapeutic oligonucleotide drug substances and drug products is described. Risk analysis of solid-phase oligonucleotide synthesis indicates that intact mass measurement is a powerful technique for confirming synthesis of the intended oligonucleotide. Further risk assessment suggests that the addition of a second, sequence-sensitive identity test, which relies on a comparison of some property of the sample to a reference standard of proven identity, results in a sufficient test of identity for most oligonucleotide drug substances and products. Alternative strategies for drug product identity testing are presented. The analysis creates a common way to communicate risk and should result in a harmonized approach to identity testing that avoids the unnecessary analytical burden associated with routine de novo sequencing, without compromising quality or patient safety.
Collapse
Affiliation(s)
- Daniel Capaldi
- Development Chemistry, Ionis Pharmaceuticals Inc., Carlsbad, California, USA
| | - Nadim Akhtar
- New Modalities and Parenteral Development and Pharmaceutical Technology & Development, Operations, AstraZeneca, Macclesfield, United Kingdom
| | - Tom Atherton
- Structure and Function Characterization, CMC Analytical, GlaxoSmithKline, Stevenage, United Kingdom
| | - David Benstead
- Chemical Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Macclesfield, United Kingdom
| | - Ayman Charaf
- Research and Development Tides, Pharmaceutical Development Platform, Sanofi-Aventis GmbH, Frankfurt am Main, Germany
| | - Thomas De Vijlder
- Analytical Development, Small Molecule Development, Janssen Pharmaceutical Companies of Johnson and Johnson, Beerse, Belgium
| | - Carl Heatherington
- Drug Substance and Product Analysis UK, CMC Analytical, GlaxoSmithKline, Stevenage, United Kingdom
| | | | - Hong Jiang
- Analytical Development, Biogen, Cambridge, Massachusetts, USA
| | - Ulrike Rieder
- Technical Research and Development, Global Drug Development, Novartis Pharma, Basel, Switzerland
| | - Francis Ring
- Development Chemistry, Ionis Pharmaceuticals Inc., Carlsbad, California, USA
| | - Robert Peter
- Analytical Research and Development, Synthetic Molecules Technical Development, F. Hoffmann-La Roche, Basel, Switzerland
| | | | - Rainer Wechselberger
- Analytical Development, Small Molecule Development, Janssen Pharmaceutical Companies of Johnson and Johnson, Beerse, Belgium
| |
Collapse
|
2
|
Freeman R, Sisson PR, Ward A, Magee JG, Heatherington C, Lightfoot NF. Mycobacterium avium-intracellulare from patients with and without AIDS compared by pyrolysis mass spectrometry. Lett Appl Microbiol 1993; 16:94-6. [PMID: 7763448 DOI: 10.1111/j.1472-765x.1993.tb00353.x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
Isolates of Mycobacterium avium-intracellulare complex (MAI) from AIDS and non-AIDS patients were compared by pyrolysis mass spectrometry (PyMS). Those from AIDS patients were more closely related to each other than those from non-AIDS patients which were significantly more disparate.
Collapse
Affiliation(s)
- R Freeman
- Microbiology Department, Medical School, Newcastle upon Tyne, UK
| | | | | | | | | | | |
Collapse
|